Ashwagandha Extracts Compared: Why Standardisation Decides
Trials used specific standardised extracts at specific doses, and an unstandardised root powder is not the same product. Withanolide content is the variable that matters.
The Short Answer
Ashwagandha is one of the better-evidenced botanicals for stress and sleep measures, and the evidence attaches to specific standardised extracts at specific doses rather than to the plant. Withanolide content is the active marker, it varies enormously between products, and an unstandardised root powder can contain a small fraction of what a trial extract delivered. Comparing products therefore means comparing standardisation, not brand claims. It also carries a real hepatotoxicity signal worth knowing about.
What Standardisation Means Here
Withanolides are the steroidal lactones regarded as the principal actives, and standardisation expresses their percentage in the extract.
Why it varies so much. Plant part matters: root and leaf differ in withanolide profile, with leaf typically higher in some withanolides including withaferin A. Extraction method, solvent and plant material quality all affect content. An unstandardised powder simply contains whatever the material happened to have.
The practical consequence. A trial using an extract standardised to 5 per cent withanolides at 600 mg delivers roughly 30 mg of withanolides. An unstandardised root powder at the same 600 mg may deliver a small fraction of that, which means the same nominal dose is not the same intervention.
What to read on a label: the plant part, the standardisation percentage, the extract ratio if given, and whether a named standardised extract is used. A label stating only ashwagandha root 600 mg is not specifying the dose of anything active.
Why branded extracts exist. The trials were run on specific preparations, so a branded standardised extract is a way of matching the studied intervention. That is a legitimate reason for a premium, and it is the only strong argument for one.
The Main Standardised Types
| Preparation type | Typical characteristics | Trial context |
|---|---|---|
| Root-only, higher-dose standardised extract | Commonly around 5 per cent withanolides, dosed 300 to 600 mg | Most trials on stress, sleep, testosterone and strength |
| Root and leaf, higher-withanolide extract | Higher standardisation percentage, dosed lower, often 125 to 250 mg | Trials on stress and cortisol measures |
| Whole-root powder, unstandardised | Variable and usually low withanolide content | Traditional use; not the trial material |
| Aqueous or specialised extracts | Varying profiles | Individual trials |
The important distinction is between root-only and root-plus-leaf preparations, because the withanolide profile differs and so does the dose. A higher standardisation percentage at a lower milligram dose is not necessarily weaker, since what matters is the withanolide amount delivered, and comparing milligrams of extract across different standardisations is meaningless.
The regulatory note on leaf: some jurisdictions restrict or discourage leaf-containing preparations, and traditional use is predominantly root. That is a consideration for anyone choosing between preparation types.
The practical calculation: multiply the dose by the standardisation percentage to get the withanolide amount, and compare that across products.
What the Evidence Supports
Stress and anxiety measures. The strongest area, with multiple randomised trials reporting reductions in perceived stress scores and in cortisol, generally over 8 to 12 weeks. Effect sizes are moderate and trial quality is variable, with several small studies and some industry involvement.
Sleep. Several trials report improved sleep quality and reduced sleep onset latency, plausibly through reduced pre-sleep arousal rather than a direct sleep mechanism.
Testosterone in men. Small trials report increases alongside reduced cortisol, which suggests it works by removing a suppressor rather than stimulating production. Modest, and it is among the few compounds in that category with any positive trial data.
Strength and body composition alongside resistance training, with small positive trials.
Thyroid. Some evidence of raised thyroid hormone levels, which is a consideration rather than a benefit and matters for anyone with thyroid disease.
Weaker areas: cognition, fertility, and general vitality claims, where trials are small and heterogeneous.
The overall picture is a botanical with better evidence than most and with the usual caveats: small trials, frequent industry funding, short durations, and effects that depend on using the studied preparation.
The Hepatotoxicity Signal
This deserves a section of its own because it is a genuine and under-communicated concern.
Case reports and case series have described liver injury associated with ashwagandha use, including cholestatic and hepatocellular patterns, some requiring hospital admission and a small number severe. Several national regulators and pharmacovigilance bodies have issued communications about it, and it appears in drug-induced liver injury registries.
Putting it in proportion. The absolute risk appears low relative to how widely the supplement is used, and idiosyncratic liver injury is unpredictable rather than dose-dependent in most reported cases. It is not a reason for alarm and it is a reason for specific caution.
Who should avoid it: anyone with existing liver disease, anyone with unexplained liver enzyme elevation, anyone taking other hepatically demanding compounds, and anyone with a prior drug-induced liver injury.
What to do if using it: know the symptoms of liver injury, which include jaundice, dark urine, pale stools, right upper quadrant pain, nausea and unexplained fatigue, and stop immediately and seek assessment if they appear. Consider baseline liver enzymes for prolonged use.
Other cautions: thyroid disease, given the thyroid hormone effects; autoimmune conditions, given immunomodulatory activity; pregnancy, where it is contraindicated; and sedative medications, given additive effects.
A Practical Comparison Method
Calculate withanolide content: dose in milligrams multiplied by standardisation percentage. Compare that number across products, not the extract weight.
Check the plant part. Root-only or root and leaf, and whether that matters in your jurisdiction.
Prefer a named standardised extract matching a trial, since that is what the evidence attaches to.
Check third-party testing, for content and for contaminants, since heavy metals have been found in some botanical products.
Match the trial dose, which for the common root extracts is 300 to 600 mg of a roughly 5 per cent standardised extract, and lower for higher-standardisation preparations.
Use it for a defined period. Trials ran 8 to 12 weeks, and indefinite use has neither trial support nor a clear rationale once the stressor has resolved.
Judge it on what you added it for: perceived stress, sleep onset, or a specific measure, assessed at 8 to 12 weeks.
Stop if any liver symptom appears, and tell your clinician you were taking it.
Applied that way, the comparison between products becomes arithmetic rather than marketing, and the compound itself becomes a time-limited trial rather than a permanent addition.
The AEONNN Perspective
Ashwagandha is where AEONNN's Quality layer is decisive rather than advisory. Withanolide content varies enormously between products, and an unstandardised root powder at the same milligram dose as a trial extract can deliver a small fraction of the active. The platform compares dose multiplied by standardisation percentage, not extract weight.
That also explains why a named standardised extract is worth a premium here when it usually is not elsewhere: the trials were run on specific preparations, so matching one is the only way to buy the studied intervention. Root-only and root-plus-leaf preparations differ in profile and dose, and some jurisdictions restrict leaf-containing products.
The Safety layer carries a signal that is under-communicated relative to how widely the supplement is used. Case reports and registries describe idiosyncratic liver injury, several regulators have issued communications, and the pattern is unpredictable rather than dose-dependent. Absolute risk appears low and it warrants specific exclusions, existing liver disease, unexplained enzyme elevation, other hepatically demanding compounds, and it is a reason the platform handles ashwagandha as a defined-period trial rather than a permanent addition.
Pillar Matrix mapping
Hormonal Optimization and Vitality, Sleep and Circadian Regulation
Database Matrix layers
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Safety Layer (DrugBank, FAERS)
- Regulatory Layer (EFSA, FDA, EMA)
Frequently Asked
Which ashwagandha extract is best?
The one matching a trial preparation at the trial dose. Compare dose multiplied by standardisation percentage to get withanolide content, since extract weight alone is not comparable.
Does standardisation matter?
Decisively. Withanolide content varies enormously, and an unstandardised root powder at the same milligram dose can deliver a small fraction of what a trial extract provided.
What dose was used in trials?
Commonly 300 to 600 mg of an extract standardised to around 5 per cent withanolides, and lower doses for higher-standardisation root and leaf preparations.
Does root or leaf matter?
Yes. The withanolide profile differs, doses differ, traditional use is predominantly root, and some jurisdictions restrict or discourage leaf-containing preparations.
Is ashwagandha safe for the liver?
Case reports and registries describe idiosyncratic liver injury, and several regulators have issued communications. Absolute risk appears low, and it warrants avoiding with existing liver disease or unexplained enzyme elevation.
Who else should avoid it?
Anyone with thyroid disease given its thyroid hormone effects, autoimmune conditions given immunomodulatory activity, pregnancy where it is contraindicated, and anyone on sedative medication.
How long should it be taken?
Trials ran 8 to 12 weeks. Indefinite use has neither trial support nor a clear rationale once the stressor it was added for has resolved.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.